Marinus Pharmaceuticals provides Ztalmy program update at investor day

Marinus Pharmaceuticals is hosting an investor and analyst day and will present an in-depth review of the company’s development program for Ztalmy oral suspension CV in tuberous sclerosis complex, or TSC, ahead of the Phase 3 TrustTSC trial topline data readout anticipated in the first half of the fourth quarter of 2024. The event begins at 9 a.m. ET and will be available via webcast here. The company said it is on track to achieve full year 2024 Ztalmy net product revenue guidance of between $33M and $35M. Full year 2024 guidance remains unchanged with projected Ztalmy net product revenue between $33 and $35 million and combined selling, general and administrative and research & development expenses in the range of approximately $135M to $140M, including stock-based compensation expense of approximately $20M. The company expects that cash and cash equivalents of $64.7M as of June 30, 2024, will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the second quarter of 2025. The company continues to make investments to expand Ztalmy manufacturing capacity necessary for the global launch of the CDKL5 deficiency disorder indication and potential TSC expansion. The company is targeting total company profitability within 18 months of a U.S. TSC launch.